Notably, increased SMC2 expression is associated with poor outcomes in patients with breast cancer (Fig. 7G), suggesting that modulation of SMC2 by CDK7 or other factors may have significant impact on the aggressiveness of this disease. This evidence concerns the gene SMC2 and breast cancer.